Johne Andreas - Global Early Dev GED Enabling Clin Scientist ECS, Merck KGaA

基本信息

浏览量：43

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 140 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

PP01.83 Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET Exon 14 (metex14) Skipping NSCLC

Frank Griesinger,Marina Garassino,Enriqueta Felip,Hiroshi Sakai,Xiuning Le,Remi Veillon,Egbert Smit,Jo Raskin,Michael Thomas,Myung-Ju Ahn, Matthew Lee,Soetkin Vlassak,Rolf Bruns,Andreas Johne,Paul K. Paik

Journal of Thoracic Oncologyno. 7 (2024): e37-e38

引用0浏览0引用

Long-term Experience with Tepotinib in Japanese Patients with MET Exon 14 Skipping NSCLC from the Phase II VISION Study

Masahiro Morise,Terufumi Kato,Shingo Matsumoto,Takako Inoue,Tomohiro Sakamoto,Takaaki Tokito,Shinji Atagi,Toshiyuki Kozuki,Hiroaki Takeoka,Kenichi Chikamori,Naofumi Shinagawa,Hiroshi Tanaka, Eisuke Horii,Svenja Adrian,Rolf Bruns,Andreas Johne,Paul K. Paik,Hiroshi Sakai

CANCER SCIENCEno. 4 (2024): 1296-1305

引用0浏览0WOS引用

Niels Reinmuth,Julien Mazieres,Sanjay Popat,Luis G. Paz-Ares, Emma S. Hook,Anthony Hatswell,Soetkin Vlassak,Andreas Johne,Helene Vioix,Paul K. Paik

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Explainable Machine Learning Prediction of Edema Adverse Events in Patients Treated with Tepotinib

Federico Amato,Rainer Strotmann, Roberto Castello,Rolf Bruns, Vishal Ghori,Andreas Johne,Karin Berghoff,Karthik Venkatakrishnan,Nadia Terranova

CTS-CLINICAL AND TRANSLATIONAL SCIENCEno. 9 (2024)

引用0浏览0WOS引用

Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION

Terufumi Kato,James Chih-Hsin Yang,Myung-Ju Ahn,Hiroshi Sakai,Masahiro Morise,Yuh-Min Chen,Ji-Youn Han,Jin-Ji Yang,Jun Zhao,Te-Chun Hsia,Karin Berghoff,Rolf Bruns,Helene Vioix, Simone Lang,Andreas Johne, Xiuning Le,Paul K. Paik

BRITISH JOURNAL OF CANCERno. 10 (2024): 1679-1686

引用0浏览0WOSNATURE引用

Supplementary Table S2 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in ≪i>egfr</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>met</i> Amplification: INSIGHT Final Analysis

Chong Kin Liam,Azura Rozila Ahmad, Te‐Chun Hsia,Jianying Zhou,Dong‐Wan Kim, Ross A. Soo,Ying Cheng,Shun Lü,Sang Won Shin,James Chih‐Hsin Yang,Yiping Zhang,Jun Zhao,Karin Berghoff,Rolf Bruns,Andreas Johne,Yi‐Long Wu

openalex（2023）

引用0浏览0引用

P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

M.-J. Ahn, T. Kato,J.C.-H. Yang, H. Sakai,M. Morise, Y.-M. Chen, J.-Y. Han,J.-J. Yang,J. Zhao,T.-C. Hsia,K. Berghoff,R. Bruns,H. Vioix, S. Lang,A. Johne,X. Le,P.K. Paik

Journal of Thoracic Oncologyno. 11 (2023): S360-S360

引用0浏览0引用

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Chong Kin Liam,Azura Rozila Ahmad, Te-Chun Hsia,Jianying Zhou,Dong-Wan Kim,Ross Andrew Soo,Ying Cheng,Shun Lu,Sang Won Shin,James Chih-Hsin Yang,Yiping Zhang,Jun Zhao,Karin Berghoff,Rolf Bruns,Andreas Johne,Yi-Long Wu

openalex（2023）

引用0浏览0引用

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Joachim Albers, Manja Friese-Hamim,Anderson Clark, Oliver Schadt,Gina Walter-Bausch,Christopher Stroh,Andreas Johne,Niki Karachaliou,Andree Blaukat

Molecular cancer therapeuticsno. 7 (2023): 833-843

引用1浏览0WOS引用

PPD02.02 Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (metamp): Final Analysis of INSIGHT

R. OHara,C. Kin Liam,A. Rozila Ahmad,T. -C. Hsia,J. Zhou,D. -W. Kim,R. Andrew Soo,Y. Cheng,S. Lu,S. Won Shin,J. Chih-Hsin Yang,Y. Zhang,J. Zhao,R. Bruns,A. Johne,Y. -L. Wu

Journal of thoracic oncologyno. 3 (2023): e6-e7

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn